Alison Bateman-House, PhD, MPH, MA is an Assistant Professor in the Division of Medical Ethics at NYU Grossman School of Medicine and a Professor of Practice in Law at University of Arizona James E. Rogers College of Law. She is co-chair, with Arthur Caplan PhD, of the Working Group on Compassionate Use and Preapproval Access (CUPA), an academic group that studies ethical issues concerning access to investigational medical products and which consists of patient advocates, clinicians, members of industry, current and former FDA staffers, lawyers, and academics, among others. Dr Bateman-House also co-chairs, with Lesha Shah MD, the Pediatric Gene Therapy and Medical Ethics (PGTME) working group, which includes academics, patient advocates, biopharmaceutical industry representatives, and a wide array of clinical and research professionals. She advises a wide array of biopharmaceutical companies, patient advocacy organizations, governmental and non-governmental entities about clinical trial design and non-trial access programs, and she serves as ethicist for multiple data safety monitoring boards overseeing clinical trials. Dr. Bateman-House also serves as the non-voting chair of the NYU/Janssen Pharmaceutical Compassionate Use Advisory Committees (CompACs) for Infectious Diseases and Neurology/Psychology. CompAC won the Reagan-Udall Foundation for the FDA’s 2019 Innovation Award. She has published and spoken extensively on non-trial access to investigational drugs, on clinical trial accessibility, on the history and ethics of using humans as research subjects, and on public health ethics.  

Alison Bateman-House, PhD, MPH, MA is an Assistant Professor in the Division of Medical Ethics at NYU Grossman School of Medicine and a Professor of Practice in Law at University of Arizona James E. Rogers College of Law. She is co-chair, with Arthur Caplan PhD, of the Working Group on Compassionate Use and Preapproval Access (CUPA), an academic group that studies ethical issues concerning access to investigational medical products and which consists of patient advocates, clinicians, members of industry, current and former FDA staffers, lawyers, and academics, among others. Dr Bateman-House also co-chairs, with Lesha Shah MD, the Pediatric Gene Therapy and Medical Ethics (PGTME) working group, which includes academics, patient advocates, biopharmaceutical industry representatives, and a wide array of clinical and research professionals. She advises a wide array of biopharmaceutical companies, patient advocacy organizations, governmental and non-governmental entities about clinical trial design and non-trial access programs, and she serves as ethicist for multiple data safety monitoring boards overseeing clinical trials. Dr. Bateman-House also serves as the non-voting chair of the NYU/Janssen Pharmaceutical Compassionate Use Advisory Committees (CompACs) for Infectious Diseases and Neurology/Psychology. CompAC won the Reagan-Udall Foundation for the FDA’s 2019 Innovation Award. She has published and spoken extensively on non-trial access to investigational drugs, on clinical trial accessibility, on the history and ethics of using humans as research subjects, and on public health ethics.